Overview
The WHO has asked the Government of India for details on alleged fake oxytocin injections supplied to hospitals in Kota, Rajasthan. Five women died after Caesarean deliveries in May 2026. Following joint inspections, the licences of two manufacturing units of Jackson Laboratories in Punjab and Himachal Pradesh were revoked.
Key Developments
- WHO sent a routine request for information to assess any public‑health risk.
- The CDSCO, together with state drug regulators, inspected the factories for compliance with GMP.
- Based on deficiencies observed, the state licensing authorities cancelled the manufacturing licences of the concerned units.
- The Union Health Ministry has asked the Rajasthan government for a detailed report on the deaths.
- Officials emphasized that WHO’s query is part of standard pharmacovigilance and should not be taken as a finding against the product.
Important Facts
Five women died between 5 May and 17 May 2026 at JK Lone Hospital and the Super Speciality Wing of Government Medical College, Kota. The suspected injections were supplied by a local distributor. The joint inspection teams reported non‑compliance with GMP, leading to licence cancellation. The WHO’s request aims to determine if the issue is confined to Kota or if the product has been exported elsewhere.
Exam Relevance
Understanding the roles of WHO, CDSCO, and state drug regulators illustrates the multi‑layered governance structure in India’s health sector. The case highlights the importance of regulatory surveillance and the need for strict adherence to GMP. Aspirants should note how public‑health emergencies trigger inter‑agency coordination and the procedural steps for licence revocation.
Way Forward
Further investigation will determine the exact cause of the deaths. The Ministry may impose additional penalties if violations are confirmed. Strengthening pharmacovigilance and ensuring strict GMP compliance are essential to prevent recurrence. Continuous monitoring by WHO and Indian regulators will help safeguard public health and maintain confidence in the pharmaceutical supply chain.